The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.

doi:10.1186/s12967-019-2100-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.

Journal of translational medicine - 4 Nov 2019

Damotte Diane, Warren Sarah, Arrondeau Jennifer, Boudou-Rouquette Pascaline, Mansuet-Lupo Audrey, Biton Jérôme, Ouakrim Hanane, Alifano Marco, Gervais Claire, Bellesoeur Audrey, Kramkimel Nora, Tlemsani Camille, Burroni Barbara, Duche Angéline, Letourneur Franck, Si Han, Halpin Rebecca, Creasy Todd, Herbst Ronald, Ren Xing, Morel Pascale, Cesano Alessandra, Goldwasser François, Leroy Karen

Abstract excerpt

BACKGROUND: The 18-gene tumor inflammation signature (TIS) is a clinical research assay that enriches for clinical benefit to immune checkpoint blockade. We evaluated its ability to predict clinical benefit of immunotherapy in cancer patients treated with PD-1 checkpoint inhibitors in routine clinical care. METHODS: The CERTIM cohort is a prospective cohort which includes patients receiving immune checkpoint...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Immunotherapy

Share to Inflammation

Share to Neoplasms

Share to Programmed Cell Death 1 Receptor

Share to Transcriptome

Share to Translational Research, Biomedical

Source

Open in PubMed Open full text

Identifiers

PMID: 31684954
DOI: 10.1186/s12967-019-2100-3
PMCID: PMC6829827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.PMID 31684954Read ↗

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).Semantic proximity Read ↗

Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor TypesSemantic proximity Read ↗

Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancersSemantic proximity Read ↗

A Large-Scale Meta-Analysis Reveals Positive Feedback between Macrophages and T Cells That Sensitizes Tumors to Immunotherapy.Semantic proximity Read ↗

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.Semantic proximity Read ↗

Identifying survival of pan-cancer patients under immunotherapy using genomic mutation signature with large sample cohorts.Semantic proximity Read ↗

Pan-cancer characterization of lncRNA modifiers of immune microenvironment reveals clinically distinct de novo tumor subtypesSemantic proximity Read ↗

PTBPs: An immunomodulatory-related prognostic biomarker in pan-cancerSemantic proximity Read ↗

Pan-cancer prediction of tumor immune activation and response to immune checkpoint blockade from tumor transcriptomics and histopathologySemantic proximity Read ↗

How Can We Improve Subtyping of Colon Adenocarcinoma for Precision Oncology? Multi-Omics Consensus Clustering Reveals Immunologically Active and Therapeutically Distinct Molecular Groups.Semantic proximity Read ↗

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.Semantic proximity Read ↗

A Multi-Omics Analysis of an Exhausted T Cells’ Molecular Signature in Pan-CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.